26
Participants
Start Date
December 15, 2017
Primary Completion Date
June 3, 2022
Study Completion Date
August 24, 2022
Microtubule-Targeted Agent BAL101553
Given PO
Radiation Therapy
Undergo radiation therapy
Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh
Abrams Cancer Center of the University of Pennsylvania, Philadelphia
Johns Hopkins University, Baltimore
Wake Forest University Comprehensive Cancer Center, Winston-Salem
Cleveland Clinic Taussig Cancer Center, Cleveland
Henry Ford Hospital, Detroit
UAB Comprehensive Cancer Center, Birmingham
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OTHER
Basilea Pharmaceutica
INDUSTRY